CAR-T Congress USA 2019 | Kisaco Research

CAR-T Congress USA

Presenting novel data to develop CAR-T into viable, accessible therapies

Download agenda
Boston, USA
16-17 April, 2019

“Outstanding comprehensive overview with top academic and industry experts.”

Juan Ruiz, Product Director, Janssen Pharmaceutical Companies of Johnson & Johnson

Why Attend

CAR-T therapy is set to revolutionize oncology pipelines and mark a new era for personalized medicine. With the recent approvals of Yescarta and Kymriah and the $11 billion acquisition of Kite, the race is on to lead the commercialization of safe, efficacious and accessible CAR-T therapy.

The fourth annual CAR-T congress USA is bringing together the leading pharmaceutical companies, the disruptive biotechs and pioneering academic institutions to assess emerging novel data and tackle the current challenges including antigen discovery, manufacturing scalability and efficacy.

Join discussions with Dr Christina Coughlin and Dr Leonard Lichtenfeld to determine how we avoid cheaper and more potent biologics hindering the progress of CAR-T, how we effectively edit T cells at scale, and how the industry is pushing for patient access to accelerate your CAR-T pipelines.

Discover first-hand the novel research being done by one of the leading ‘biotechs to watch’ Tmunity, as we explore the potential of CAR-T switches to control and manage CAR-T therapy effectively. Join Fate Therapeutics, TCR2 and Cellectis to determine how novel CAR-T constructs and gene editing technology are paving the way for the next generation CAR-Ts.

With two tracks for preclinical discovery and clinical development, refine your methods from optimizing T cell phenotypes and longevity to providing quality control for robust manufacturing. With sessions ran by Gilead and Legend Biotech on strengthening the business strategy for CAR-T and global regulation sessions ran by the EMA, this is your chance to be informed when commercialising your CAR-T therapy.

Be part of the movement that engineers a strategy to reprogram the cancer treatments we know today.

Take a look at our highlights video from 2018:

CAR-T 2018 IMAGE GALLERY

CAR-T image gallery

TESTIMONIALS

CAR-T USA testimonials

WHO WILL BE THERE

Network with industry experts from:

  • Big pharma and biotech
  • Cell Therapy Academics and clinicians 
  • Process standardisation - technology/services
  • Logistics companies - cell storage/transport
  • Service providers - CRO’s, Consultants, Government

Past attendees include:

CAR-T Usa Logo Cloud

The Agenda

Take a look at our agenda preview for the hot topics we'll be covering. Please fill in your details so we know who to send this too. 

CAR-T USA Agenda Front Cover

Check out the highlights from 2018: 

Download Agenda

We need some information to know where to send the link and how to address our email to you. Please note, a link to the PDF will also become immediately available once this form is submitted.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

The Speakers

 

Kim Nguyen, PhD

Director, CMC
Precision Biosciences

Kim is a part of the Cell Therapy team at Precision Biosciences focused on the process development, analytics, and manufacturing of allogeneic CAR-T cell products. Before joining Precision Biosciences, she served as Principal Scientist and Senior Manager for Strategic Initiatives at Terumo BCT. Kim received her AB from Princeton University and her Ph.D. from Columbia University, both in Chemistry. She enjoys cooking Vietnamese food, reading, and adventures with her adorable Jack Russell terrier, Grover, aka Mr. Shambles.

Kim Nguyen, PhD

Director, CMC
Precision Biosciences

Kim Nguyen, PhD

Director, CMC
Precision Biosciences

Kim is a part of the Cell Therapy team at Precision Biosciences focused on the process development, analytics, and manufacturing of allogeneic CAR-T cell products. Before joining Precision Biosciences, she served as Principal Scientist and Senior Manager for Strategic Initiatives at Terumo BCT. Kim received her AB from Princeton University and her Ph.D. from Columbia University, both in Chemistry. She enjoys cooking Vietnamese food, reading, and adventures with her adorable Jack Russell terrier, Grover, aka Mr. Shambles.

 

Robert Hofmeister

Chief Scientific Officer
TCR2

Robert Hofmeister

Chief Scientific Officer
TCR2

Robert Hofmeister

Chief Scientific Officer
TCR2
 

Dan Shoemaker

Chief Scientific Officer
Fate Therapeutics

Dan Shoemaker

Chief Scientific Officer
Fate Therapeutics

Dan Shoemaker

Chief Scientific Officer
Fate Therapeutics
 

Ali Mohamed

VP CMC
Immatics Biotechnologies

Ali Mohamed

VP CMC
Immatics Biotechnologies

Ali Mohamed

VP CMC
Immatics Biotechnologies
 

Paul Lammers

President & CEO
Triumvira Immunologics

Paul Lammers

President & CEO
Triumvira Immunologics

Paul Lammers

President & CEO
Triumvira Immunologics
 

Professor David Miklos

Professor
Stanford University Medical Center

Professor David Miklos

Professor
Stanford University Medical Center

Professor David Miklos

Professor
Stanford University Medical Center
 

Therese Solstad Saunders

Senior Scientific Advisor
Norwegian Medicines Agency

Therese Solstad Saunders

Senior Scientific Advisor
Norwegian Medicines Agency

Therese Solstad Saunders

Senior Scientific Advisor
Norwegian Medicines Agency
 

Professor Saar Gill

Professor
Department of Medicine, University of Pennsylvania

Professor Saar Gill

Professor
Department of Medicine, University of Pennsylvania

Professor Saar Gill

Professor
Department of Medicine, University of Pennsylvania
 

Professor Sattva Neelapu

Department of Lymphoma and Myeloma, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center

Professor Sattva Neelapu

Department of Lymphoma and Myeloma, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center

Professor Sattva Neelapu

Department of Lymphoma and Myeloma, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
 

Peter Emtage

Cell Design Labs

Dr. Emtage currently serves as Chief Scientific Officer at Cell Design Labs, Inc. (CDL). Prior to joining CDL, he was Vice President of Synthetic Immunology at Intrexon Corporation and was Vice President of Immune Mediated Therapy in the Oncology Innovative Medicines group at Medimmune. At Medimmune, Dr. Emtage designed and implemented a comprehensive immune therapy cancer strategy. He has over sixteen years of biologics development experience in the fields of oncology, autoimmunity, infectious diseases, and inflammation. Dr. Emtage holds a B.S. and M.S.

Peter Emtage

Cell Design Labs

Peter Emtage

Cell Design Labs

Dr. Emtage currently serves as Chief Scientific Officer at Cell Design Labs, Inc. (CDL). Prior to joining CDL, he was Vice President of Synthetic Immunology at Intrexon Corporation and was Vice President of Immune Mediated Therapy in the Oncology Innovative Medicines group at Medimmune. At Medimmune, Dr. Emtage designed and implemented a comprehensive immune therapy cancer strategy. He has over sixteen years of biologics development experience in the fields of oncology, autoimmunity, infectious diseases, and inflammation. Dr. Emtage holds a B.S. and M.S. in Molecular Biology and Genetics from the University of Guelph and received his Ph.D. in Molecular Virology, Immunology and Inflammation at McMaster University. At the beginning of his career, he also was a post-doctoral fellow at the National Institutes of Health and held roles at Aventis Pasteur and Harvard Medical School.

 

Dr. John McHutchinson

Chief Scientific Officer & Head of Research and Development
Gilead

Dr. John McHutchinson

Chief Scientific Officer & Head of Research and Development
Gilead

Dr. John McHutchinson

Chief Scientific Officer & Head of Research and Development
Gilead
 

Dr. Christina Coughlin

Chief Medical Officer & Executive Vice President
Tmunity

Dr. Christina Coughlin

Chief Medical Officer & Executive Vice President
Tmunity

Dr. Christina Coughlin

Chief Medical Officer & Executive Vice President
Tmunity
 

Hans-Peter Gerber

CSO & SVP
3T Biosciences

Hans-Peter Gerber

CSO & SVP
3T Biosciences

Hans-Peter Gerber

CSO & SVP
3T Biosciences
 

Dr. Alexandre Juillerat

Laboratory Head
Cellectis

Dr. Alexandre Juillerat

Laboratory Head
Cellectis

Dr. Alexandre Juillerat

Laboratory Head
Cellectis
 

Dr. Leonard Lichtenfeld

Acting Chief Medical Officer
American Cancer Society

Dr. Leonard Lichtenfeld

Acting Chief Medical Officer
American Cancer Society

Dr. Leonard Lichtenfeld

Acting Chief Medical Officer
American Cancer Society
 

Dr. Francesco Galimi

Global Product General Manager, Early Development
Amgen Inc

Dr. Francesco Galimi

Global Product General Manager, Early Development
Amgen Inc

Dr. Francesco Galimi

Global Product General Manager, Early Development
Amgen Inc
 

Dr. Avery Posey

Department of Pathology and Laboratory Medicine
University of Pennsyvania

Dr. Avery Posey

Department of Pathology and Laboratory Medicine
University of Pennsyvania

Dr. Avery Posey

Department of Pathology and Laboratory Medicine
University of Pennsyvania
 

Dr. Saul Priceman

Assistant Research Professor
Department of Hematology & Hematopoietic Cell Transplantation, City of Hope

Dr. Saul Priceman

Assistant Research Professor
Department of Hematology & Hematopoietic Cell Transplantation, City of Hope

Dr. Saul Priceman

Assistant Research Professor
Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
 

Fred Koller, Ph.D.

Executive Vice President, Business Development
Miltenyi Biotech

Fred Koller, Ph.D.

Executive Vice President, Business Development
Miltenyi Biotech

Fred Koller, Ph.D.

Executive Vice President, Business Development
Miltenyi Biotech
 

Welf Ludwig

Manager, Sales & Business Consulting
Werum IT Solutions

Welf Ludwig

Manager, Sales & Business Consulting
Werum IT Solutions

Welf Ludwig

Manager, Sales & Business Consulting
Werum IT Solutions
 

Dr. Qiong Wang

Senior Director of R&D
Legend Biotech

Dr. Qiong Wang

Senior Director of R&D
Legend Biotech

Dr. Qiong Wang

Senior Director of R&D
Legend Biotech
 

Dr. Matthew Spear

Chief Medical Officer
Poseida Therapeutics

Dr. Matthew Spear

Chief Medical Officer
Poseida Therapeutics

Dr. Matthew Spear

Chief Medical Officer
Poseida Therapeutics
 

Dr. Kristen Hege

VP Translational Development
Celgene

Dr. Kristen Hege

VP Translational Development
Celgene

Dr. Kristen Hege

VP Translational Development
Celgene
 

Rob Margolin

VP Corporate Development and Strategy
Trakcel

Rob Margolin

VP Corporate Development and Strategy
Trakcel

Rob Margolin

VP Corporate Development and Strategy
Trakcel
 

Dominic Clarke

Global Head of Cell Therapy
Hemacare

Dominic Clarke

Global Head of Cell Therapy
Hemacare

Dominic Clarke

Global Head of Cell Therapy
Hemacare
 

Ryan Crisman, PhD

Executive Director
Gates Biomanufacturing Facility

Ryan Crisman, PhD

Executive Director
Gates Biomanufacturing Facility

Ryan Crisman, PhD

Executive Director
Gates Biomanufacturing Facility
 

Dr Angeliki Grammenos

RA Manager
Celyad

Angeliki has held positions in academia and biopharma, with a special focus in cell therapy.

Angeliki is a physicist by training and has a PhD in biophysics specialized in cell biology. She left her teaching position at the University of Liège in 2012, to join the international office of Doctors Without Borders where she assisted the Ethical review board as well as the Quality Assurance department of the movement.

Dr Angeliki Grammenos

RA Manager
Celyad

Dr Angeliki Grammenos

RA Manager
Celyad

Angeliki has held positions in academia and biopharma, with a special focus in cell therapy.

Angeliki is a physicist by training and has a PhD in biophysics specialized in cell biology. She left her teaching position at the University of Liège in 2012, to join the international office of Doctors Without Borders where she assisted the Ethical review board as well as the Quality Assurance department of the movement.

In 2015, she joined Bone Therapeutics S.A, a biopharmaceutical company dedicated to the development of cell therapy products based on autologous and allogeneic adult stem cell technology to treat unmet medical needs in the field of bone disease where she led the RA Department.

In 2018, Angeliki joined Celyad, a biopharmaceutical company specialized in autologous and allogeneic cell therapy. Celyad’s core business lies in immune-oncology and the development of NK-receptor based CAR T therapies.

 

Dr. Leon Song

Director for Business Development, Biologics Development Business Unit
GenScript

Dr. Leon Song

Director for Business Development, Biologics Development Business Unit
GenScript

Dr. Leon Song

Director for Business Development, Biologics Development Business Unit
GenScript
 

Dawn Driscoll

CEO
Cell Therapies

Dawn Driscoll

CEO
Cell Therapies

Dawn Driscoll

CEO
Cell Therapies
 

Madhusudan Peshwa

Global Head of R&D for Cell & Gene Therapy
GE

Madhusudan Peshwa

Global Head of R&D for Cell & Gene Therapy
GE

Madhusudan Peshwa

Global Head of R&D for Cell & Gene Therapy
GE
 

Stefano Baila

Anemocyte S.R.L

Stefano Baila received his PhD in 2007 based upon translational research and development of gene therapies for hemophilia at the Children’s Hospital of Philadelphia.  Since that time he has been actively involved in the process development and manufacturing of advanced therapeutic medicinal products through business development and strategic marketing roles at Areta International, a CDMO, and by leading field implementation and commercialization activities for the cell processing unit of Terumo BCT.

Stefano Baila

Anemocyte S.R.L

Stefano Baila

Anemocyte S.R.L

Stefano Baila received his PhD in 2007 based upon translational research and development of gene therapies for hemophilia at the Children’s Hospital of Philadelphia.  Since that time he has been actively involved in the process development and manufacturing of advanced therapeutic medicinal products through business development and strategic marketing roles at Areta International, a CDMO, and by leading field implementation and commercialization activities for the cell processing unit of Terumo BCT. Stefano also worked as Industrialization Manager at Celyad where he led process development and automation efforts for CAR-T therapeutics. Now he serves as Director of Operation and Business Development for Anemocyte.

Headline Partner

Platinum Partners

Gold partners

Event Partners

Media Partners

Become a Sponsor

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

Venue

Hyatt Regency Boston Harbor, 101 Harborside Drive, Boston, MA 02128

This year's 4th Annual CAR-T Congress will be taking place in Hyatt Regency Boston Harbor, 101 Harborside Drive, Boston, MA 02128

Hyatt Regency Boston Harbor is an intimate and boutique-style Harborside hotel with breathtaking views of the beautiful city skyline. Guests will appreciate the proximity to Logan Airport and the hotel’s complimentary airport shuttle. Boston’s famed cultural and historical sites, recreational options, and neighborhoods are just minutes away and easily accessible through our many public transportation options available including the MBTA Train and Water Taxi.

Unfortunately, there are no rooms available at the Hyatt Regency, please contact the Embassy Suites Hotel near Logan Airport who have rooms available. The Embassy Suites Hotel is a 6-minute taxi from the Hyatt Regency or alternatively, there is a free shuttle bus between the hotels.

Hyatt Regency Harbour Hotel

Accessibility:

We are committed to making our event accessible to everyone. If you are traveling for the event, Cloud of Goods provides mobility scooter rentals, wheelchair rentals, and other mobility solutions. They will deliver directly to you at the event, your hotel, the airport, or any other place of your choosing. Event attendees will receive a 20% discount when they use the code: RENTGEAR032

Visit: https://www.cloudofgoods.com/ 

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Preparing registration...

Resources

Download Resource

We need some information to know where to send the link and how to address our email to you. Please note, a link to the PDF will also become immediately available once this form is submitted.

You may withdraw this consent at any time by emailing us at [email protected].
To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us

Kisaco Research
Registered office address: 41a Maltby Street, London, SE1 3PA
+44 (0)20 3696 2920 | [email protected]
Place of registration: London, United Kingdom
Company number: 09316521

We need some information to know how best to respond to your request below.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

Other events you might be interested in:

CAR-T Congress EU 2019

Therapeutic Genome Editing Congress

European Protein Degradation Congress